| Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript |
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ET Company Participants Rushmie Nofsinger - VP, Corporate Affairs and IR David Hallal - CEO Akshay Vaishnaw - President of R&D Keith Woods - COO Vikas Sinha - CFO Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan David Nierengarten - Wedbush Gary Nachman - Raymond James Kripa Devarakonda - Truist Marc Frahm - TD Cowen Andres Maldonado - H.C. Wainwright Dennis Kennedy - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-14 16:30:08 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the first quarter ended March 31, 2025. “Scholar Rock is at an inflection point as we evolve to a commercial-stage biopharmaceutical company, and our team remains focused on key prioritie. |
businesswire.com |
2025-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET. To access the live conference call, participants may register here. The live audio web. |
businesswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards to R. Keith Woods, its newly named Chief Operating Officer and Vikas Sinha, its newly named Chief Financial Officer, covering an aggregate of up to 1,420,134 shares of its common stock, con. |
businesswire.com |
2025-05-06 20:15:00 |
Czytaj oryginał (ang.) |
| Why Scholar Rock Stock Took a Knock on Monday |
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making. |
fool.com |
2025-04-28 23:08:07 |
Czytaj oryginał (ang.) |
| Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion buildi. |
businesswire.com |
2025-04-28 10:50:00 |
Czytaj oryginał (ang.) |
| Why Scholar Rock Holding Stock Topped the Market Today |
Biotech stock Scholar Rock (SRRK 2.97%) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day. |
fool.com |
2025-04-23 22:34:45 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and. |
businesswire.com |
2025-04-18 20:15:00 |
Czytaj oryginał (ang.) |
| FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for. |
businesswire.com |
2025-03-25 09:30:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment |
Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. |
benzinga.com |
2025-03-17 14:21:32 |
Czytaj oryginał (ang.) |
| Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &a. |
businesswire.com |
2025-03-16 21:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to p. |
businesswire.com |
2025-03-14 18:15:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript |
Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. |
seekingalpha.com |
2025-02-27 15:23:35 |
Czytaj oryginał (ang.) |
| Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March. |
businesswire.com |
2025-02-21 10:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to. |
businesswire.com |
2025-02-14 18:15:00 |
Czytaj oryginał (ang.) |
| Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data |
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. |
seekingalpha.com |
2025-01-30 10:37:15 |
Czytaj oryginał (ang.) |
| Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu. |
businesswire.com |
2025-01-29 10:05:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to pu. |
businesswire.com |
2025-01-17 18:15:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth |
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference. |
benzinga.com |
2025-01-15 16:23:15 |
Czytaj oryginał (ang.) |
| Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET). A live webcast of the presentation may be accesse. |
businesswire.com |
2025-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to. |
businesswire.com |
2024-12-13 18:15:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study |
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity. |
benzinga.com |
2024-11-25 13:51:46 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to pu. |
businesswire.com |
2024-11-15 18:15:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript |
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. |
seekingalpha.com |
2024-11-12 13:09:08 |
Czytaj oryginał (ang.) |
| Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conf. |
businesswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for I. |
businesswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that on October 16, 2024, the underwriters of its previously announced underwritten public offering of common stock and pre-funded warrants, which closed on October 10, 2024,. |
businesswire.com |
2024-10-22 12:00:00 |
Czytaj oryginał (ang.) |
| Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? |
Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. |
zacks.com |
2024-10-21 14:55:24 |
Czytaj oryginał (ang.) |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 23,500 shares of its common stock to two newly hired employees, consisting of inducement stock options to purc. |
businesswire.com |
2024-10-18 20:15:00 |
Czytaj oryginał (ang.) |
| Here's Why Everybody's Talking About Scholar Rock Right Now |
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers. |
fool.com |
2024-10-09 09:38:00 |
Czytaj oryginał (ang.) |
| Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 10,265,488 shares of its common stock at a public offering price of $28.25 per share and, in lieu of common stock to. |
businesswire.com |
2024-10-09 03:08:00 |
Czytaj oryginał (ang.) |
| SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal |
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal. |
zacks.com |
2024-10-08 16:03:20 |
Czytaj oryginał (ang.) |
| Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial |
Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The positive results indicate that the apitegromab monoclonal antibody significantly improves motor function in patients. |
gurufocus.com |
2024-10-08 02:10:42 |
Czytaj oryginał (ang.) |
| Scholar Rock: SMA Program Strides Forward With Positive Clinical Data |
Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. |
seekingalpha.com |
2024-10-07 21:29:39 |
Czytaj oryginał (ang.) |
| Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that it has commenced an underwritten public offering for $275 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warra. |
businesswire.com |
2024-10-07 20:09:00 |
Czytaj oryginał (ang.) |
| Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher |
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. |
benzinga.com |
2024-10-07 16:00:18 |
Czytaj oryginał (ang.) |
| Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophy |
The Phase 3 trial of Apitegromab showed statistically significant improvement in motor function. |
marketwatch.com |
2024-10-07 12:20:00 |
Czytaj oryginał (ang.) |
| Scholar Rock to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in. |
businesswire.com |
2024-08-29 12:00:00 |
Czytaj oryginał (ang.) |
| Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say |
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday. |
marketwatch.com |
2024-08-26 16:00:00 |
Czytaj oryginał (ang.) |